NSCLC cells with BRAF mutations where shown to be more sensitive to MEK inhibitors than NSCLC with mutations in EGFR, KRAS, or the chimeric fusion between ALK and ROS [101]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.